John W. Smither
Director · NewAmsterdam Pharma Co N.V.
IndividualSelling only
- 2025
- Sep 9, 2026
- 6
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies John W. Smither files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Michael H. Davidson - $25.55M in NAMS purchases and sales in the last 12 months
- Louise Frederika Kooij - $16.75M in NAMS purchases and sales in the last 12 months
- Johannes Jacob Pieter Kastelein - $15.52M in NAMS purchases and sales in the last 12 months
- Mayur Ian Somaiya - $3.43M in NAMS purchases and sales in the last 12 months
- Salomon Azoulay - $2.72M in MBX purchases and sales in the last 12 months
- Louis G. Lange - $2.19M in NAMS purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is John W. Smither?
John W. Smither is a corporate insider, tracked as Director of NewAmsterdam Pharma Co N.V. (NAMS). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has John W. Smither submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has John W. Smither been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($75K) across all tracked filings.
